Clinical TrialsMRT-2359 has shown encouraging activity in heavily pretreated CRPC patients previously exposed to androgen receptor targeted agents.
Financial PerformanceGLUE reported Q1 net income of $47MM and cash of $331MM (runway into 2028).
PartnershipsMonte Rosa's lead I&I asset, MRT-6160, is advancing toward multiple Phase 2 trials, supported through a partnership with Novartis.